Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

RS-5614 studied in investigator-initiated trial for severe COVID-19

Dec. 2, 2020

New COMMUNITY adaptive platform trial for COVID-19 begins enrollment

Dec. 1, 2020

DMX-200 selected for inclusion in CLARITY 2.0 study for COVID-19

Dec. 1, 2020

Antiviral novaferon exhibits anti-SARS-CoV-2 effects both at cellular level and in COVID-19 patients

Dec. 1, 2020

Moderna to file for EUA of mRNA-1273 for COVID-19 following primary efficacy analysis

Nov. 30, 2020

Janssen discovers anti-HBV compounds

Nov. 30, 2020

COLCORONA trial of colchicine in COVID-19 recommended to continue enrollment

Nov. 30, 2020

SmartPharm awarded contract for development of gene-encoded antibody against COVID-19

Nov. 30, 2020

Researchers develop a novel murine model of deer tick virus infection

Nov. 30, 2020

Initiation of phase I/II study of NGM-621 as therapy in patients with SARS-CoV-2 infection

Nov. 30, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...